The advanced programme eHealth Business receives new support by Innosuisse


Institutional Communication Service

26 May 2020

In this time of health crisis, digital technologies have proved to be an essential tool for identifying, tracing and treating diseases. The new eHealth Business programme, developed by USI Center of Advanced Studies on Entrepreneurship in Biomedicine (CASE BioMed), fits perfectly into this context in which information technology and entrepreneurship in the health sector are playing an increasingly important role. Recognising the programme's concrete contribution to current challenges, Innosuisse renews its support for the future editions.

Support for entrepreneurship, innovation and technology transfer in the life sciences sector is an important building block for USI, even more central in a context where the health emergency has led to new challenges. USI Faculty of Biomedical Sciences with its advanced training courses offered by CASE BioMed has immediately taken into account the shifting conditions and has striven to ensure an offer that meets current needs, creating spaces in which to encourage the promotion and support of new applications of digital technologies in the health sector, which will be fundamental for the prevention and management of future pandemics. It is in this context that Innosuisse has responded positively to the call of CASE BioMed by renewing its support for the new eHealth Business programme. With an important financial contribution, Innosuisse wanted to emphasise the importance of such programmes and guarantee future editions: "This contribution will be used to finance 34 scholarships for the most deserving participants. The innovative concept of this programme, which aims to respond to the challenges of a new sector that is evolving very rapidly, becomes even more vital in this particular situation to provide participants with training that can give entrepreneurs the tools to grow a business in eHealth," explains Dr. Heidrun Flaadt Cervini, Director of CASE BioMed.


More information about CASE BioMed available here: